Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1126
Shown on this page
12
Current sort
Recently updated
Campus scope
Northwestern Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Northwestern Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 997–1008 of 1,126 matching trials with a site at Northwestern Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting Phase 2 Interventional Results available

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

NCT02143726
Site status not listed — check the official record
View directory record Official record
Conditions
Refractory Hurthle Cell Thyroid Cancer
Interventions
sorafenib, everolimus
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
21
States / cities
Jacksonville, Florida • Chicago, Illinois • Sioux City, Iowa + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Recruiting Phase 2Phase 3 Interventional

FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial

NCT06062888
Status at this site: Recruiting
View directory record Official record
Conditions
Moderate to Severe Traumatic Brain Injury
Interventions
Fresh Frozen Plasma (FFP)
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluate the Continued Safety and Performance of the Foot and Ankle Products

NCT04715139
Status at this site: Recruiting
View directory record Official record
Conditions
Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.), Medial Ankle Stabilization, Tibiotalocalcaneal Arthrodesis
Interventions
Products listed in Group/Cohort Description
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
2 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

NCT07036133
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors, Hematologic Malignancies
Interventions
Pralatrexate Injection
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Cerritos, California • Chicago, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
Site status not listed — check the official record
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Recruiting Not applicable Interventional

His-Bundle Corrective Pacing in Heart Failure

NCT05265520
Status at this site: Recruiting
View directory record Official record
Conditions
Right Bundle-Branch Block, Heart Failure, His-bundle Pacing, Cardiac Resynchronization Therapy
Interventions
His-CRT implantation, BIV-CRT implantation
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting No phase listed Observational

Thoraflex Hybrid and Relay Extension Post-Approval Study

NCT05639400
Site status not listed — check the official record
View directory record Official record
Conditions
Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
Interventions
Thoraflex Hybrid, RelayPro NBS
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Timeline
2023 – 2036
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting Phase 3 Interventional

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

NCT04455750
Site status not listed — check the official record
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
414
States / cities
Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Recruiting Not applicable Interventional

Electrophysiological Representations of Odor Identity Study 2

NCT07386236
Status at this site: Recruiting
View directory record Official record
Conditions
Odor Identity Ratings
Interventions
odor
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
12 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting No phase listed Observational

Artificial Intelligence Patient App for RDEB SCCs

NCT05843994
Site status not listed — check the official record
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
online survey
Other
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 5, 2026, 2:14 PM EST
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
Site status not listed — check the official record
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 5, 2026, 2:14 PM EST

About this Northwestern Medicine institution page

What this page lists
ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Northwestern University at any site, browse by condition, or browse by U.S. city.